EGFR and lung adenocarcinoma: Since almost all the EGFR-mutant NSCLCs were lung adenocarcinoma (more than 95% in ADAURA trial), EGFR TKI, instead of sequential chemoradiotherapy, was currently the standard of treatment for stage IIIA-N2 EGFR-mutant lung adenocarcinoma after complete resection.